(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The many ways that baking is winter therapy. With a delicious ending - 2It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- 3Family-Accommodating Snow Sports Experiences
- 4Vote in favor of your #1 sort of juice
- 5Startled Venezuelans express relief but also fear after Maduro arrest
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- Israeli president concerned over proposed renaming of park
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Vote in favor of your Number one method for commending a birthday
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
- DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- Ukraine's new defense minister just outlined how dire its troop shortage has become
